Abstract: Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (WHO) adverse drug reaction (ADR) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug-drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87-year-old female Croatian/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles CYP2C9
Dual antiplatelet therapy and statins, the cornerstone of acute coronary syndrome (ACS) treatment, are generally safe and well tolerated [1] . Ticagrelor and rosuvastatin are often prescribed together because it is theoretically assumed that there is no significant interaction between these two drugs. Primary elimination of both drugs by biliary excretion and renal function is not considered particularly important. Muscle symptoms are the most prevalent adverse drug reactions (ADRs) of statins, among them the most serious being rhabdomyolysis with a substantially elevated serum creatine kinase (CK). Rhabdomyolysis depends on the statin dose and the presence of other risk factors causing an elevation of statin concentration [2, 3] such as pharmacokinetic interactions [4] which can be affected by differences in interindividual pharmacogenetics characteristics [5] .
Until now, no interactions of ticagrelor and rosuvastatin have been described with the consideration of pharmacogenetic predisposition at the level of Cytochrome P450 enzymes (CYPs) and drug transporters, and it was considered only theoretically important. This is the first case where the pharmacogenetic characteristics of a patient are described which has the potential to contribute to the development of severe ADR rhabdomyolysis.
Statins differ in their affinity for metabolic enzymes and drug transporters [5, 6] . They are transported by several polymorphic ABC (MRP2/ABCC2, MDR1/ABCB1, ABCG2) and SLC (OATP1B1/SLCO1B1) drug transporters (involved in the process of absorption, distribution and elimination) and have also been shown to compete with other drugs for transport by these proteins [7, 8] . In the SEARCH genomewide association study (GWAS) SLCO1B1 c.521T>C (rs4149056) gene variant encoding for low-activity OATP1B1 drug transporter was associated with an 18% risk of muscle symptoms with high-dose simvastatin therapy compared to 3% in heterozygotes, while the risk was 0.6% in those without a variant allele [9] . For rosuvastatin, the influence of OATP1B1 is less significant, and other pharmacogenes such as ABCG2 seem to be more relevant [10, 11] . Considering CYPs, atorvastatin, simvastatin and lovastatin are metabolized predominantly by CYP3A4/5, fluvastatin by CYP2C9, while rosuvastatin biotransformation is partly dependent on CYP2C9 [5] . For the metabolism in Phase II, UGT enzymes have the main role.
Ticagrelor is a direct oral, reversibly binding P2Y12 inhibitor, frequently used as a component of dual antiplatelet therapy in ACS [12] . CYP3A4/5 are the enzymes predominantly responsible for the metabolism of ticagrelor. As rosuvastatin clearance is not dependent on CYP3A4/5, it would seem that the combination of rosuvastatin and ticagrelor has less potential to provoke serious adverse reactions, including rhabdomyolysis [5, 13] . In the Summary of Product Characteristics (SmPC) of either medicinal product, an interaction between these two active substances is not listed [14, 15] .
We present all available published cases on the rosuvastatin-ticagrelor interaction and discuss the possible role of gene variability in drug metabolism and transport referring to the published literature; only for our patient, pharmacogenetic data are available and we present these in detail.
Case Presentation
The case presents rosuvastatin-and ticagrelor-induced rhabdomyolysis in a patient with chronic renal insufficiency. Possible multifactorial causes for rhabdomyolysis following the concomitant use of rosuvastatin and ticagrelor, such as old age, polypharmacy, renal impairment, along with pharmacogenetics, are discussed.
On 6 May 2017, an 87-year-old female Caucasian was admitted to the Department of Cardiovascular Diseases due to symptoms and signs of rhabdomyolysis. Her past medical history revealed chronic renal failure, arterial hypertension and ACS with percutaneous coronary intervention when rosuvastatin and ticagrelor were initiated, 1 month prior hospital admission. Several days before hospitalization, she began feeling progressive fatigue, muscle weakness and pain in both her forearms and tights. Her therapy upon admission was as follows: acetyl salicylic acid 100 mg, ticagrelor 2 9 90 mg, furosemide 40 mg, potassium 1 g, rosuvastatin 20 mg, pantoprazole 40 mg, amiodarone 200 mg and bisoprolol 2.5 mg. At admission, her blood pressure was 185/77 mmHg, heart rate 80 per minutes and physical examination showed no major abnormalities except muscle pain and weakness. Urine output was preserved. Electrocardiogram (ECG) showed sinus rhythm without signs of ischaemia, in comparison with prior ECG recordings. Laboratory parameters were hs-cTnT 239 ng/L, serum CK 19,182 U/L, creatinine 306 lmol/L, eGFR MDRD 13.3 mL/min/1.73 m 2 , liver enzymes (ALT 352 U/L, GGT 49 U/L, ALP 72 U/L) and red cells (+++) in qualitative urine analysis, all suggesting that the patient had developed rhabdomyolysis. One month earlier, her creatinine level was 201 lmol/L; hence, progression of chronic renal failure was also apparent. Rosuvastatin and amiodarone were immediately excluded from the therapy assuming that rhabdomyolysis was caused by this drug interaction as amiodarone has the potential to interact with many drugs [16] [17] [18] . The hallmark biomarker for muscle injury is CK level in serum; it rises within 12 hr of muscle injury, but has its peak value at 24-72 hr with a serum halflife of approximately 1.5 days. A CK value greater than 15,000 U/L may be predictive for acute renal failure development [19] . According to laboratory findings, parenteral rehydration was initiated, with preserved urine excretion. Due to high blood pressure at admission, amlodipine was introduced at dose of 5 mg/day, but was discontinued from therapy 3 days later as blood pressure values decreased. Despite immediate rosuvastatin and amiodarone discontinuation from therapy, but according to the kinetic rate of serum CK, CK rose further in the next 2 days to a value of 23,974 U/L. On the 5th day of hospitalization, a mild decrease in CK value was noted, but the creatine concentration rose to 393 lmol/L and symptoms of fatigue, muscle weakness and myalgias remained unchanged. Taking into account all symptoms and laboratory data, in consultation with a nephrologist, initiation of haemodialysis was considered; however, the patient refused. On the 7th day of hospitalization, ticagrelor was discontinued from therapy, as a literature review was performed resulting in two articles which suggested that an interaction between ticagrelor and statins could precipitate rhabdomyolysis [13, 20] . Unfortunately, the patient was refused daily blood sampling consequently making daily CK values during hospitalization unavailable. On the 9th day, a rapid normalization of CK level was recorded ( fig. 1 ). From the day of ticagrelor discontinuation (day 7), the patient declared regression of clinical symptoms with a complete recovery in the next few days. On day 10, a trend of mild renal function improvement was noted, but complete recovery of renal function was neither achieved nor expected regardless of ticagrelor as the patient had a history of chronic renal impairment ( fig. 1 ). The patient was discharged from the hospital after 13 days in good overall state. Therapy at discharge was as follows: acetyl salicylic acid 100 mg, clopidogrel 75 mg, furosemide 80 mg, potassium 1 g and pantoprazole 40 mg and bisoprolol 2.5 mg daily ( fig. 2) . Six months later, a clinical and laboratory follow-up was performed together with a pharmacogenetic analysis of relevant genes coding for metabolic enzymes and drug transporters. At the follow-up clinical examination, the patient was in good condition, without muscle symptoms, taking all recommended medications. Her control laboratory analysis showed no further progression of renal insufficiency, with a creatinine level of 304 lmol/L and potassium level of 4.3 mmol/L while CK and hepatic enzymes remained at normal levels.
Methods
Genotyping procedures. Pharmacogenetic analyses for the presented patient were performed in an accredited laboratory.
For genotyping, 3 mL of blood samples was collected in Na-EDTA tubes. Genomic DNA was extracted from whole blood using iPrep â PureLink â gDNA Blood Kit (Invitrogen, Carlsbad, CA, USA) on the AutoMate Express TM DNA Extraction System (Applied Biosystems, Foster City, CA, USA).
Genotyping of CYP2C9*2 (rs4244285), CYP2C9*3 (rs1057910), CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560), CYP2D6*3 (rs35742686), CYP2D6*4 (rs3892097), CYP2D6*6 (rs5030655), CYP2D6*41 (rs28371725), CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) and UGT2B7 -161C>T (rs7668258) was performed using 
Results

Pharmacogenetic analysis.
Analysis showed that the patient was a heterozygous carrier of the inactivating alleles (CYP2C9*1/*3, CYP3A4*1/*22, CYP3A5*3, CYP2D6*1/*4, UGT2B7 -161C/T), predisposing for slower than expected metabolism of drug substrates; UGT1A1*28/*28 predisposing for poor metabolism/conjugation (Gilbert syndrome). Additionally, the patient had, according to genotypes, normal metabolism by CYP2C19 (CYP2C19*1/*1) intermediate P-glycoprotein activity (ABCB1 3435C/T, 1237 C/T), a high activity of OATP1B (SLCO1B1 521TT) and ABCG2 (421CC).
Database search results.
As of 28 January 2017, VigiBase, the WHO global database of individual case safety reports, contained five well-documented reports, not including the patient presented in this case. In 2017, two more case reports were published by Samuel et al. [21] and New et al. [22] . In the literature, several reports present cases where concomitantly prescribed rosuvastatin and ticagrelor resulted in rhabdomyolysis development. The authors concluded that the impairment of renal function by ticagrelor can increase the concentration of rosuvastatin which potentially can lead to myopathy or even rhabdomyolysis [17, 20] . The pharmacogenetic predisposition of the patient, which could be the trigger for a clinical significant interaction between these two active substances, was only theoretically outlined.
Discussion
Statins are the most widely prescribed drugs to prevent coronary heart disease and stroke. There is considerable interindividual variation in susceptibility to the most common adverse statin effect, myopathy. Although there are convincing data that genetic profile can result in increased statin serum concentrations which are linked to muscle side effects [5, 9, 24] , genetic testing in patients with statin-induced myopathy has not yet been translated into clinical practice. Several reasons for this exist, including insufficient understanding of this issue by health professionals, absence of sufficiently strong evidence linking the results of testing with clinical outcomes and lack of cost-benefit analysis. Polytherapy is a potential cause of statin ADRs. Concomitant treatment with a statin and drug(s) that inhibit CYPs, ABC and SLC drug transporters (OATP1B1, ABCB1, ABCG2) has been associated with increased risk of new or worsening muscle pain [2] . In addition, pharmacogenetic predisposition can be relevant for modulating plasma concentrations of statins and in turn statin-drug interactions and/or ADRs.
Pharmacogenetic testing has been mainly used retrospectively to identify and explain ADRs or therapeutic failure in individual patient [25, 26] . According to our knowledge, this is the first published case with a retrospective pharmacogenetic testing after the ADR of rhabdomyolysis induced by an interaction between rosuvastatin and ticagrelor was suspected. The risk of developing statin-induced rhabdomyolysis is concentration-dependent; it is increased in elderly patients and in patients with renal and/or hepatic impairment. Our patient had several risk factors for statin-induced rhabdomyolysis: advanced age, female gender and chronic renal failure [2] . It is important to underline that in our patient, the rosuvastatin dose was not properly adjusted for pre-existing renal insufficiency and advanced age. The applied dosage of rosuvastatin was 20 mg, but for the patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m 2 ), dosing of rosuvastatin should be started at 5 mg and not exceed 10 mg once daily. Reduction in the dose is also recommended in elderly patients as higher doses are more frequently associated with ADRs [14] . A possible impact of ticagrelor was noticed in this case. Despite immediate exclusion of rosuvastatin, the main positive turn in symptoms and rapid CK decrease was noticed shortly after ticagrelor was stopped. The similar clinical course was described in case report by van Vuren et al. [20] . Besides stopping the rosuvastatin on day one, the authors also noticed clinical recovery and CK decrease just after discontinuation of ticagrelor. Above that, their patient was taking rosuvastatin for several years without symptoms, and ticagrelor was the only medication started a month prior to the occurrence of rhabdomyolysis. Co-administration of rosuvastatin and ticagrelor started also in our patient one month prior to the onset of rhabdomyolysis. As both drugs were initiated simultaneously, it is difficult to predict whether rhabdomyolysis is caused by drug-drug interactions or simply as an adverse reaction to rosuvastatin exposure. The same time relationship of 1 month between rhabdomyolysis and concomitant exposure of rosuvastatin and ticagrelor was observed in three other cases reported in VigiBase (table 1) [23] .
VigiBase, the WHO global database of individual case safety reports, contained five well-documented reports, not including the patient presented in this case. In four of these five patients, age was involved (70, 76, 78 and 82 years), and in one case, a 46-year-old male patient experienced rhabdomyolysis. Two of the elderly male patients received the maximum daily dose of 40 mg of rosuvastatin, one received 20 mg, and the dose remains unknown for the fourth; the younger patient received 20 mg of rosuvastatin daily. The status of renal function was not captured or stated for these patients, except in the case of a 78-year-old patient in whom a rise of the creatinine level was observed 1 week after the introduction of ticagrelor -from 108 to 124 lmol/L, which refers to a decrease in glomerular filtration from 60 to 52 mL/min. [9, 11] . For the 46-year-old patient, renal function was not recorded but he was taking lisinopril, an ACE inhibitor, which can also alter renal function. Two patients were, along with rosuvastatin, taking ezetimibe at the same time, which is known to increase the AUC of rosuvastatin. Ezetimibe was given to the 76-and 78-year-old patients (cases 1 and 5 in table 1), who were already taking the highest dose of rosuvastatin (40 mg) [23] . In 2017, two more case reports were published. Samuel and collaborators described a case of drug interaction between rosuvastatin and ticagrelor, resulting in rhabdomyolysis and acute renal failure necessitating dialysis in a 49-year-old African-American female [21] . The patient was also taking lisinopril and prior to hospitalization, she attended a rigorous exercise routine at a cardiac rehabilitation centre 3 days per week which resulted in significant weight loss for a couple of months. New and collaborators reported a case of acute renal failure and rhabdomyolysis in a 66-yearold woman with concomitant use of rosuvastatin, ticagrelor and losartan [22] . This patient also had a dose of rosuvastatin (40 mg/day) greater than recommended, considering her chronic renal disease, and time relationship between rhabdomyolysis and concomitant exposure of rosuvastatin and ticagrelor was 6 weeks. To date, three possible mechanisms of ticagrelor's influence on rosuvastatin elimination/disposition are described:
1 Renal impairment caused by ticagrelor, leading to decreased renal excretion of rosuvastatin. 2 Competition on transporter level (OATP1B1, P-glycoprotein, ABCG2, MRP2), leading to decreased biliary and renal excretion of rosuvastatin. 3 Genetic polymorphism of metabolic enzymes (CYPs, UGTs) and drug transporters, leading to the increased competition between drugs. All three mechanisms are outlined in more detail below:
Renal impairment.
The most studied possible interaction is renal impairment caused by ticagrelor leading to a decreased renal excretion of rosuvastatin. The exact mechanism leading to the worsening of renal function by ticagrelor is unknown, but the PLATO trial showed that serum creatinine concentration was increased by more than 30% in 25.5% of the patients receiving ticagrelor. Worsening of the renal function was more pronounced in patients over 75 years of age, in patients receiving angiotensin receptor inhibitors and patients with pre-existing renal dysfunction [21, 27, 28] . It is speculated that inhibition of adenosine reuptake by ticagrelor reduces glomerular filtration rate through vasoconstriction of the afferent renal arteriole [22, 29] .
However, there are no recommendations regarding modification of ticagrelor dosage in patients with reduced renal function as the primary route of ticagrelor elimination is via hepatic metabolism. Recoveries of ticagrelor and the active metabolite in urine were both <1% of the dose. Also, the primary route of elimination for the active metabolite is most likely via biliary secretion [15] .
Competition on transporter level.
The second mechanism of ticagrelor interaction with rosuvastatin elimination is mainly by decreasing biliary and to some extent renal excretion. The interaction not only between rosuvastatin and ticagrelor but also possibly with other concomitantly prescribed medicines could be driven by competition on the level of P-glycoprotein, MRP2, ABCG2, OATP1B1 [2, 3, 5, 6, 29] . For example, ticagrelor and its metabolite are substrates and inhibitors of P-glycoprotein [30] which also could have added to drug-drug interaction (DDI) with other P-gp substrates (in our case rosuvastatin and amiodarone). Previously, it was discovered that co-administration of ticagrelor and digoxin (high-affinity P-gp substrate) in healthy volunteers resulted in a 75% and 28% increase in digoxin Cmax and AUC, respectively [31] . Rosuvastatin is cleared primarily by biliary excretion but also by a significant renal clearance where data suggested that the apical exit of rosuvastatin is mediated largely by ABCG2 and MRP2/4 and, to a lesser extent, by MDR1/ABCB1. It was shown that net rosuvastatin secretory flux was reduced in the presence of P-gp inhibitor, vinblastine, by $ 30%. Inhibition of the secretory flux was accompanied by a concomitant proportional increase in intracellular rosuvastatin concentration in the presence of vinblastine (7.8 AE 0.2 lM; p < 0.05) versus no inhibitor (2.8 AE 0.1 lM) [7] .
Genetic polymorphism.
Although only 10% of rosuvastatin is metabolized by the CYP2C9 enzyme, in our patient carrying 2C9*3 and UGT2B7 -161T, low-activity allele could have some influence on rosuvastatin disposition. Besides, ticagrelor is both a substrate and mild inhibitor of CYP3A4/5. Our patient being carrier of inactivating allele CYP3A4*22 and non-expresser of 3A5 could have prolonged ticagrelor disposition and even higher potential for renal impairment and DDI. In patients treated with ticagrelor in the PLATO trial, ticagrelor pharmacokinetics was influenced by three genetic loci (CYP3A4, UGT2B7 and SLCO1B1) [32] . Although genetic effects on ticagrelor plasma concentration levels did not translate into any detectable ADRs in that study, altered ticagrelor pharmacokinetics could be relevant for modulation of its interaction with other drugs.
We also propose one additional mechanism that could have added to risk of rhabdomyolysis. Lactones in relation to the acid form of statins are stronger inducers of toxicity. Lactones can be induced by glucuronidation via UDP-glucuronosyltransferase. The study performed by Schirris et al. [33] showed that for six clinically relevant statins, only UGT1A1, 1A3 and 2B7 significantly contributed to their lactonization. Polymorphisms in UGT1A1, 1A3 and 2B7 regions could contribute to myopathy caused by statins. Authors concluded that knowing these polymorphisms could be used to personalize statin therapy and improve their safety [33] . Our patient was heterozygous for UGT2B7 and homozygous for UGT1A1 lowactivity alleles what also could have contributed to rosuvastatin toxicity. Furthermore, other concomitantly prescribed drugs could have -to some extent -influenced rosuvastatin and/or ticagrelor pharmacokinetics in our patient. Proton pump inhibitors show an inhibitory effect for CYP2C9, 2C19, 2D6 and 3A4 enzymes, which can result in DDI with other concomitantly, prescribed drug substrates [34] . The extent of this inhibition could be even more relevant in patients (like it is in our case) with already impaired metabolism due to inactivating variants CYP2C9*3, CYP2D6*4 and CYP3A4*22. Distribution of drug metabolism enzymes and transporters involved in possible mechanisms of presented ADRs are shown in fig. 3 . In the presented patient, DDI with amiodarone could have also added to the ADR risk potential. Like rosuvastatin and ticagrelor, amiodarone is primarily eliminated by hepatic metabolism and biliary excretion. It has a long half-life of 58 days (range 15-142 days). The interactions between amiodarone and other drugs including statins are well known and documented [16, 17, 35] . They may occur via the inhibition of CYP activities, where amiodarone inhibits CYP3A4, while its metabolite desethylamiodarone inactivates CYP1A1, CYP1A2, CYP2B6, CYP2C9 and CYP2D6 [36] . Amiodarone has also the potential for interactions with drugs or substances that are substrates of P-gp. As toxicity of amiodarone also includes hepatotoxicity, the elevated liver enzymes seen in the presented case can be attributed to rosuvastatin and amiodarone, and values normalized after the drugs were withdrawn.
Taking into account the results of pharmacogenetic tests, recommendations by Clinical Pharmacogenetics Implementation Consortium Guidelines (CPIC) and renal impairment, the use of clopidogrel appears to be more appropriate than ticagrelor for this patient. Being a CYP2C19-extensive metabolizer, this will ensure good conversion of the prodrug (clopidogrel) to its active form. In addition, it is expected that the use of pantoprazole (also substrate of CYP2C19) will be safe in that combination. Our patient accepted the initiation of clopidogrel, but refused the idea of reinitiating a low dose of any statin. Regarding the use of statins in this patient due to impaired metabolism by CYP3A4/5 and CYP2C9, although there are still no official recommendations, we believe that simvastatin, atorvastatin, lovastatin and rosuvastatin, if applied, should be administered at rather low doses. However, in our opinion, due to the possibility that some drugs which are inhibitors of CYP3A4 (such as azoles, some antibiotics and many others) could be applied¸especially in such elderly patients, an alternative statin-like pravastatin (metabolism not dependent on CYPs) could prove to be a better solution.
Conclusions
In some patients, concomitant use of ticagrelor could affect rosuvastatin plasma concentrations, leading to rhabdomyolysis. The patients in whom the ADR was reported were at high risk of rhabdomyolysis, being elderly with renal impairment and initially on inappropriate/excessive dose of rosuvastatin. Adding ticagrelor to this condition gave the additional hazard of increasing the rosuvastatin concentration to a critical level, resulting in rhabdomyolysis. Ticagrelor can alter both the hepatic and renal pathways of rosuvastatin. Besides ticagrelor, other concomitantly applied drugs should be considered as an additional source of DDI. Pharmacogenetic analysis of metabolic enzymes and drug transporters can provide information about genetic predisposition for these interactions and help in tailoring not only an individual statin and antiplatelet therapy but also recommend dosage of other prescribed drugs. By this approach, pharmacogenetics could help maintain the efficacy and avoid the risk of severe, life-threatening ADRs as a result of the DDI. Patients at high risk of rhabdomyolysis including advanced age or chronic renal impairment after initiation of ticagrelor and rosuvastatin should be closely monitored for renal function (creatinine level) as recommended in the SmPC for ticagrelor and start therapy with a minimum dose of 5 mg rosuvastatin, as is recommended in the SmPC for rosuvastatin.
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